Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates - Brahmer, J R; Drake, C G; Wollner, I (J Clin Oncol, 2010)
et al.